Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 77 results for hypersensitivity

  1. Prostatitis (acute): antimicrobial prescribing (NG110)

    This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

  2. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

    Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.

  3. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

  4. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

  5. Infliximab for the treatment of adults with psoriasis (TA134)

    Evidence-based recommendations on infliximab for treating severe psoriasis in adults.

  6. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  7. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  8. Drug allergy (QS97)

    This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.

  9. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

  10. Oral health for adults in care homes (NG48)

    This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.

  11. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  12. Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.

  13. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

  14. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

  15. DuraGraft for preserving vascular grafts (MIB184)

    NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .